Latest Articles

Publication Date
TMEM119 Links to Ovarian Endometriosis Progression via MAPK-Mediated Suppression of Ectopic Endometrial Stromal Cell Senescence.

Transmembrane protein TMEM119 has been implicated in tumor progression (e.g., ovarian cancer), but its role and underlying mechanism in ovarian endometriosis (EM) remain elusive. Thus, this study aimed to investigate …

Published: Feb. 19, 2026, midnight
Primary Amenorrhea With Bilateral Endometriomas in a Teenager Girl With Cervical Hypoplasia and Vaginal Agenesis.

A rare case of primary amenorrhea caused by cervical hypoplasia and vaginal agenesis highlights the critical need for early diagnosis and timely surgical intervention to prevent severe complications such as …

Published: Feb. 19, 2026, midnight
The Paradox of Endometriosis in Mayer-Rokitansky-Kuster-Hauser Syndrome: Applying Three Criteria to Discriminate Between Retrograde Menstruation/Implantation and Coelomic Metaplasia/Embryonic Cell Rests Theories.

Background/Objectives: The scientific community is still divided between supporters of the implantation theory and researchers who advocate the theory of coelomic metaplasia/embryonic cell remnants to explain the initiation of endometriosis. …

Published: Feb. 19, 2026, midnight
Body fat percentage associated with endometriosis severity in cross-sectional analysis - Contemporary OB/GYN

Body fat percentage associated with endometriosis severity in cross-sectional analysis Contemporary OB/GYN

Published: Feb. 18, 2026, 8:38 p.m.
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - PharmiWeb.com

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement PharmiWeb.com

Published: Feb. 18, 2026, 4:05 p.m.
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider

Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider

Published: Feb. 18, 2026, 3:28 p.m.
Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider

Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider

Published: Feb. 18, 2026, 3:28 p.m.
FimmCyte Partners with Gedeon Richter to Advance Non-Hormonal Endometriosis Treatment - Femtech Insider

FimmCyte Partners with Gedeon Richter to Advance Non-Hormonal Endometriosis Treatment Femtech Insider

Published: Feb. 18, 2026, 3:18 p.m.
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - The AI Journal

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement The AI Journal

Published: Feb. 18, 2026, 1:25 p.m.
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - Business Wire

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement Business Wire

Published: Feb. 18, 2026, 1 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!